

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	P glycoprotein (MDR1; ABCB1; P-gp; CD243)	<i>In vitro</i> studies suggest the generic small molecule tiopronin could help treat multidrug-resistant cancers. In cancer cells expressing MDR1, an efflux pump that ejects drugs from the blood brain barrier (BBB) and causes multidrug resistance, tiopronin destabilized MDR1 and increased sensitivity to the generic chemotherapeutics doxorubicin and paclitaxel compared with no treatment. Next steps include showing the effects of tiopronin against multidrug-resistant tumors <i>in vivo</i> . Hanmi Pharmaceutical Co. Ltd. has Oraxol, a formulation of paclitaxel plus an MDR1 inhibitor, in Phase II testing to treat cancer.	Patent application filed; available for licensing	Goldsborough, A.S. <i>et al. J. Med. Chem.</i> ; published online June 9, 2011; doi:10.1021/jm2001663 <b>Contact:</b> Michael M. Gottesman, National Institutes of Health, Bethesda, Md. e-mail: <a href="mailto:gottesmm@mail.nih.gov">gottesmm@mail.nih.gov</a>
		<b>SciBX 4(27); doi:10.1038/scibx.2011.763</b> Published online July 14, 2011		